TG Therapeutics, Inc. (TGTX)
31.98
+1.38
(+4.51%)
USD |
NASDAQ |
Dec 11, 16:00
32.00
+0.02
(+0.06%)
After-Hours: 20:00
TG Therapeutics Cash from Investing (Quarterly): 46.36M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amgen, Inc. | -414.00M |
| Karyopharm Therapeutics, Inc. | 4.805M |
| Axsome Therapeutics, Inc. | -0.058M |
| Krystal Biotech, Inc. | -4.286M |
| Arcutis Biotherapeutics, Inc. | -25.25M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -23.15M |
| Cash from Financing (Quarterly) | -78.24M |
| Free Cash Flow | -70.24M |
| Free Cash Flow Per Share (Quarterly) | -0.1443 |
| Free Cash Flow to Equity (Quarterly) | -23.23M |
| Free Cash Flow to Firm (Quarterly) | 78.17M |
| Free Cash Flow Yield | -1.36% |